About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Massachusetts | 601 Studies

Clinical Trials LymphomaMassachusetts

Lymphoma Clinical Trials in Massachusetts

Find 601 clinical trials for lymphoma near Massachusetts. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Massachusetts

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 241-260 of 601 trials

CompletedCombination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.NCT00032019·Anniston, Alabama and 80 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedSafety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersThis is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior…NCT03037645·Orange, California and 10 others

CompletedA Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaThe goal of the study is to identify a dose and schedule of CC-486 that can be safely administered with R-CHOP.NCT02343536·Tampa, Florida and 6 others

CompletedA Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin LymphomaThe purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab…NCT01974440·Gilbert, Arizona and 134 others

TerminatedPanobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaPanobinostat is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes.NCT01282476·Boston, Massachusetts and 2 others

CompletedWTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaA first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.NCT05678998·Scottsdale, Arizona and 8 others

TerminatedStudy to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLStudy to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLLNCT05360238·Orange, California and 5 others

CompletedA Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaThe purpose of this study is to evaluate the preliminary efficacy, safety, and pharmacokinetics of glofitamab (glofit) in combination with rituximab plus ifosfamide, carboplatin…NCT05364424·Orange, California and 8 others

RecruitingPembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaThis is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including…NCT05313243·New Haven, Connecticut and 1 other

CompletedBortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin LymphomaRATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.NCT00598169·La Jolla, California and 16 others

CompletedStudy to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent AsthmaStudy to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent…NCT02105012·Athens, Alabama and 40 others

Active not recruitingDS-3201b in Participants With LymphomasDS-3201b is an experimental drug that is being investigated in clinical research.NCT02732275·Duarte, California and 19 others

TerminatedEvent-Related Potential (ERP) Components in Clinical DiagnosisIn this study, the investigators will use a novel electroencephalogram (EEG) system that participants will wear during a single in-person research session to investigate whether…NCT05673759·Boston, Massachusetts

CompletedBone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous TherapyRATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.NCT00005988·Boston, Massachusetts and 1 other

WithdrawnImpact of Vorinostat on Pruritus Signaling Pathways - Merck StudyMycosis Fungoides (MF) is a rare malignancy in the United States. It is the most common form of cutaneous T-cell lymphoma (CTCL).NCT01801670·Boston, Massachusetts

RecruitingInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyThis phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute…NCT03959085·Birmingham, Alabama and 230 others

CompletedHigh Dose Rituximab for Initial Treatment of Indolent B-Cell LymphomasThe purpose of this clinical trial is to see if increased doses of rituximab are safe and effective for the initial treatment of indolent B-cell lymphomas.NCT00895661·Boston, Massachusetts and 1 other

Active not recruitingDose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell LymphomaThis phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late…NCT03681535·Boston, Massachusetts and 11 others

Active not recruitingA Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell LymphomaThis phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating…NCT04115631·Anchorage, Alaska and 503 others

CompletedBendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular LymphomaRATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping…NCT01216683·Greenbrae, California and 226 others

PreviousPage 13 of 31Next

Other Conditions in Massachusetts

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia